Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(4)
•••
Post by FredZarfloonon Oct 30, 2019 5:44pm
174 Views
Post# 30288955

Cayman doesn't need Antibe for ATB-346

Cayman doesn't need Antibe for ATB-346They have "the right" to make and sell the product.

From: "TechServ"
Sent: Wednesday, October 30, 2019
Subject: RE: ATB-346 Item No. 16234
.
Dear *****,
.
Thank you for your communication.  We supply research grade compounds intended for laboratory research purposes only.  It is our current understanding that we have the right to make and sell this product.  If this should change, we will contact you.  We strongly encourage our customers to seek their own legal counsel with regard to freedom-to-operate issues.  I hope this information is helpful.  Please feel free to contact techserv@caymanchem.com with future technical questions. 
.
Best wishes,
Technical Support Representative
Cayman Chemical Company
www.caymanchem.com
.
From: 
Sent: Wednesday, October 30, 2019
Subject: Re: ATB-346 Item No. 16234
.
Thank you for replying. Is Cayman's ATB-346 a different compound than Antibe's ATB-346? If so, how is it different and does Cayman hold it's own ATB-346 patent separate from Antibes ATB-346 patent.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities